| Dr Michael Noparstak, DO | |
|
150 High St, Ellsworth, ME 04605-1761 | |
| (207) 222-3112 | |
| Not Available |
| Full Name | Dr Michael Noparstak |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 9 Years |
| Location | 150 High St, Ellsworth, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881057594 | NPI | - | NPPES |
| DO2935 | Other | ME | MAINE OSTEOPATHIC PHYSICIAN LICENSE |
| UO4767 | Other | FL | FLORIDA OSTEOPATHIC RESIDENT LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | UO4767 (Florida) | Secondary |
| 207N00000X | Dermatology | DO2935 (Maine) | Primary |
| Entity Name | Acadia Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972132843 PECOS PAC ID: 5890116321 Enrollment ID: O20200609000447 |
News Archive
Four new AIDS medicines are this week being added to the World Health Organization prequalification list, thus further increasing access to a choice of quality products.
Alvogen, the US-based pharmaceutical company, today announced that its India-based partner, Natco Pharma Limited, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the generic version of Tamiflu.
The upcoming spate of patent expirations bodes well for the European generics market. The growing loss of patent protection on blockbuster brands over the next few years, coupled with the rising need to contain spiralling healthcare costs, is set to provide a fillip to market expansion.
Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, today announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Noparstak, DO 150 High St, Ellsworth, ME 04605-1761 Ph: () - | Dr Michael Noparstak, DO 150 High St, Ellsworth, ME 04605-1761 Ph: (207) 222-3112 |
News Archive
Four new AIDS medicines are this week being added to the World Health Organization prequalification list, thus further increasing access to a choice of quality products.
Alvogen, the US-based pharmaceutical company, today announced that its India-based partner, Natco Pharma Limited, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the generic version of Tamiflu.
The upcoming spate of patent expirations bodes well for the European generics market. The growing loss of patent protection on blockbuster brands over the next few years, coupled with the rising need to contain spiralling healthcare costs, is set to provide a fillip to market expansion.
Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, today announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.
› Verified 9 days ago